By Kris B. Mamula, Pittsburgh Business Times
Cancer diagnostics company Cernostics announced Tuesday it had received two patents in the United States and a third patent in Japan.
The patents pertain to different aspects of the Uptown Pittsburgh company’s TissueCypher™ technology platform.
“These patents are an important part of our intellectual property strategy and provide our technology platform with long term market exclusivity,” CEO Mike Hoerres said in a prepared statement. “No other diagnostics technology can replicate our tissue systems biology approach to anatomic pathology – the TissueCypher™ playform will bring unique, actionable information to the health care community.”